Brief: Adocia Initiates 3-Week Phase 1B Study Of ADO09

Adocia SA

06/06/2019 17:10

June 6 (Reuters) - ADOCIA SA  ADOC.PA :
    * ADOCIA INITIATES A 3-WEEK PHASE 1B STUDY OF ADO09, A
CO-FORMULATION OF PRAMLINTIDE AND MEALTIME INSULIN, IN PEOPLE
WITH TYPE 1 DIABETES
    * STUDY COMPLETION IS EXPECTED IN Q4 2019
    * PRIMARY ENDPOINT IS EFFECT OF ADO09, COMPARED TO PRANDIAL
INSULIN NOVOLOG(®), ON POSTPRANDIAL GLYCEMIC CONTROL AT END OF A
24-DAY TREATMENT PERIOD
    * THIS STUDY WILL DOCUMENT THE SAFETY AND EFFICACY OF ADO09
OVER A
24-DAY PERIOD OF REPEAT ADMINISTRATION, INCLUDING AN OUTPATIENT
PORTION, AIMING TO INFORM FURTHER CLINICAL DEVELOPMENT

Source text for Eikon:  ID:nBwbWXKTwa 
Further company coverage:  ADOC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))